J. Hernando

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial

J. Capdevila, Salvatore Tafuto, Merete Krogh, Àlex Teulé et autres

Background Everolimus or streptozotocin plus 5-fluorouracil (STZ/5-FU) are approved treatments for patients with pancreatic neuroendocrine tumors (panNETs). The SEQTOR trial aimed to assess the optimal treatment sequence. Patients and methods SEQTOR was an international, open-label, randomized, crossover, phase III trial that recruited …

es, it, dk, nl, de, se, fr, gb (code pays fourni par la source)

1035MO A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs): Results from NUTRIGETNE (GETNE-S2109) study

Marta del Olmo, Miguel Antonio Sampedro-Nuñez, R. Garcia-Carbonero, J. Hernando et autres

es (code pays fourni par la source)

1940TiP Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design

A. García Álvarez, Beatriz Castelo Fernández, Carlos López, Javier Martínez‐Trufero et autres

es (code pays fourni par la source)

2224P Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry

Minchan Gil, J. Hernando, A.R. Granados, Alberto Carmona‐Bayonas et autres

es (code pays fourni par la source)

1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial

Jaume Capdevila Castillón, Maria Plana, B. Castelo, L. Iglesias et autres

es (code pays fourni par la source)

496MO Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin

María Carmen Riesco Martínez, Jaume Capdevila Castillón, V. Alonso, Paula Jimenez-Fonseca et autres

es (code pays fourni par la source)

The diagnostic utility of human papillomavirus-testing in combination with immunohistochemistry in advanced gynaecologic pelvic tumours: A new diagnostic approach

Tjoung‐Won Park, Oliver Zivanovic, Ingo Theuerkauf, Barbara Dürkop et autres

Gynaecologic pelvic tumours comprise a range of histological entities that are highly variable with respect to their clinical behaviour. The distinction of these tumours can be extremely difficult. Accurate identification of the primary tumour site has significant impact on the treatment strategy …

de (code pays fourni par la source)